Global Age Related Macular Degeneration Drugs Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Description

According to our (Global Info Research) latest study, the global Age Related Macular Degeneration Drugs market size was valued at USD 7949.4 million in 2023 and is forecast to a readjusted size of USD 11680 million by 2030 with a CAGR of 5.6% during review period.

Age-related macular degeneration (AMD) is a disease that blurs the sharp, central vision you need for “straight-ahead” activities such as reading, sewing, and driving. AMD affects the macula, the part of the eye that allows you to see fine detail.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

The Global Info Research report includes an overview of the development of the Age Related Macular Degeneration Drugs industry chain, the market status of 50-60 Years Old (Lucentis, Eylea), 60-70 Years Old (Lucentis, Eylea), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Age Related Macular Degeneration Drugs.

Regionally, the report analyzes the Age Related Macular Degeneration Drugs markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Age Related Macular Degeneration Drugs market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:
The report presents comprehensive understanding of the Age Related Macular Degeneration Drugs market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Age Related Macular Degeneration Drugs industry.

The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K MT), revenue generated, and market share of different by Type (e.g., Lucentis, Eylea).

Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Age Related Macular Degeneration Drugs market.

Regional Analysis: The report involves examining the Age Related Macular Degeneration Drugs market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Age Related Macular Degeneration Drugs market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Age Related Macular Degeneration Drugs:
Company Analysis: Report covers individual Age Related Macular Degeneration Drugs manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Age Related Macular Degeneration Drugs This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (50-60 Years Old, 60-70 Years Old).

Technology Analysis: Report covers specific technologies relevant to Age Related Macular Degeneration Drugs. It assesses the current state, advancements, and potential future developments in Age Related Macular Degeneration Drugs areas.

Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Age Related Macular Degeneration Drugs market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

Market Segmentation
Age Related Macular Degeneration Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.

Market segment by Type
    Lucentis
    Eylea
    Avastin
    Squalamine
    Conercept
    Lampalizamab
    Others

Market segment by Application
    50-60 Years Old
    60-70 Years Old
    Others

Major players covered
    Novartis
    Bayer Healthcare
    Roche
    Neurotech Pharmaceuticals
    Regeneron Pharmaceuticals
    Allergan

Market segment by region, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Age Related Macular Degeneration Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Age Related Macular Degeneration Drugs, with price, sales, revenue and global market share of Age Related Macular Degeneration Drugs from 2019 to 2024.
Chapter 3, the Age Related Macular Degeneration Drugs competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Age Related Macular Degeneration Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Age Related Macular Degeneration Drugs market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Age Related Macular Degeneration Drugs.
Chapter 14 and 15, to describe Age Related Macular Degeneration Drugs sales channel, distributors, customers, research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Age Related Macular Degeneration Drugs
    1.2 Market Estimation Caveats and Base Year
    1.3 Market Analysis by Type
        1.3.1 Overview: Global Age Related Macular Degeneration Drugs Consumption Value by Type: 2019 Versus 2023 Versus 2030
        1.3.2 Lucentis
        1.3.3 Eylea
        1.3.4 Avastin
        1.3.5 Squalamine
        1.3.6 Conercept
        1.3.7 Lampalizamab
        1.3.8 Others
    1.4 Market Analysis by Application
        1.4.1 Overview: Global Age Related Macular Degeneration Drugs Consumption Value by Application: 2019 Versus 2023 Versus 2030
        1.4.2 50-60 Years Old
        1.4.3 60-70 Years Old
        1.4.4 Others
    1.5 Global Age Related Macular Degeneration Drugs Market Size & Forecast
        1.5.1 Global Age Related Macular Degeneration Drugs Consumption Value (2019 & 2023 & 2030)
        1.5.2 Global Age Related Macular Degeneration Drugs Sales Quantity (2019-2030)
        1.5.3 Global Age Related Macular Degeneration Drugs Average Price (2019-2030)

2 Manufacturers Profiles
    2.1 Novartis
        2.1.1 Novartis Details
        2.1.2 Novartis Major Business
        2.1.3 Novartis Age Related Macular Degeneration Drugs Product and Services
        2.1.4 Novartis Age Related Macular Degeneration Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.1.5 Novartis Recent Developments/Updates
    2.2 Bayer Healthcare
        2.2.1 Bayer Healthcare Details
        2.2.2 Bayer Healthcare Major Business
        2.2.3 Bayer Healthcare Age Related Macular Degeneration Drugs Product and Services
        2.2.4 Bayer Healthcare Age Related Macular Degeneration Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.2.5 Bayer Healthcare Recent Developments/Updates
    2.3 Roche
        2.3.1 Roche Details
        2.3.2 Roche Major Business
        2.3.3 Roche Age Related Macular Degeneration Drugs Product and Services
        2.3.4 Roche Age Related Macular Degeneration Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.3.5 Roche Recent Developments/Updates
    2.4 Neurotech Pharmaceuticals
        2.4.1 Neurotech Pharmaceuticals Details
        2.4.2 Neurotech Pharmaceuticals Major Business
        2.4.3 Neurotech Pharmaceuticals Age Related Macular Degeneration Drugs Product and Services
        2.4.4 Neurotech Pharmaceuticals Age Related Macular Degeneration Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.4.5 Neurotech Pharmaceuticals Recent Developments/Updates
    2.5 Regeneron Pharmaceuticals
        2.5.1 Regeneron Pharmaceuticals Details
        2.5.2 Regeneron Pharmaceuticals Major Business
        2.5.3 Regeneron Pharmaceuticals Age Related Macular Degeneration Drugs Product and Services
        2.5.4 Regeneron Pharmaceuticals Age Related Macular Degeneration Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.5.5 Regeneron Pharmaceuticals Recent Developments/Updates
    2.6 Allergan
        2.6.1 Allergan Details
        2.6.2 Allergan Major Business
        2.6.3 Allergan Age Related Macular Degeneration Drugs Product and Services
        2.6.4 Allergan Age Related Macular Degeneration Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.6.5 Allergan Recent Developments/Updates

3 Competitive Environment: Age Related Macular Degeneration Drugs by Manufacturer
    3.1 Global Age Related Macular Degeneration Drugs Sales Quantity by Manufacturer (2019-2024)
    3.2 Global Age Related Macular Degeneration Drugs Revenue by Manufacturer (2019-2024)
    3.3 Global Age Related Macular Degeneration Drugs Average Price by Manufacturer (2019-2024)
    3.4 Market Share Analysis (2023)
        3.4.1 Producer Shipments of Age Related Macular Degeneration Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2023
        3.4.2 Top 3 Age Related Macular Degeneration Drugs Manufacturer Market Share in 2023
        3.4.2 Top 6 Age Related Macular Degeneration Drugs Manufacturer Market Share in 2023
    3.5 Age Related Macular Degeneration Drugs Market: Overall Company Footprint Analysis
        3.5.1 Age Related Macular Degeneration Drugs Market: Region Footprint
        3.5.2 Age Related Macular Degeneration Drugs Market: Company Product Type Footprint
        3.5.3 Age Related Macular Degeneration Drugs Market: Company Product Application Footprint
    3.6 New Market Entrants and Barriers to Market Entry
    3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region
    4.1 Global Age Related Macular Degeneration Drugs Market Size by Region
        4.1.1 Global Age Related Macular Degeneration Drugs Sales Quantity by Region (2019-2030)
        4.1.2 Global Age Related Macular Degeneration Drugs Consumption Value by Region (2019-2030)
        4.1.3 Global Age Related Macular Degeneration Drugs Average Price by Region (2019-2030)
    4.2 North America Age Related Macular Degeneration Drugs Consumption Value (2019-2030)
    4.3 Europe Age Related Macular Degeneration Drugs Consumption Value (2019-2030)
    4.4 Asia-Pacific Age Related Macular Degeneration Drugs Consumption Value (2019-2030)
    4.5 South America Age Related Macular Degeneration Drugs Consumption Value (2019-2030)
    4.6 Middle East and Africa Age Related Macular Degeneration Drugs Consumption Value (2019-2030)

5 Market Segment by Type
    5.1 Global Age Related Macular Degeneration Drugs Sales Quantity by Type (2019-2030)
    5.2 Global Age Related Macular Degeneration Drugs Consumption Value by Type (2019-2030)
    5.3 Global Age Related Macular Degeneration Drugs Average Price by Type (2019-2030)

6 Market Segment by Application
    6.1 Global Age Related Macular Degeneration Drugs Sales Quantity by Application (2019-2030)
    6.2 Global Age Related Macular Degeneration Drugs Consumption Value by Application (2019-2030)
    6.3 Global Age Related Macular Degeneration Drugs Average Price by Application (2019-2030)

7 North America
    7.1 North America Age Related Macular Degeneration Drugs Sales Quantity by Type (2019-2030)
    7.2 North America Age Related Macular Degeneration Drugs Sales Quantity by Application (2019-2030)
    7.3 North America Age Related Macular Degeneration Drugs Market Size by Country
        7.3.1 North America Age Related Macular Degeneration Drugs Sales Quantity by Country (2019-2030)
        7.3.2 North America Age Related Macular Degeneration Drugs Consumption Value by Country (2019-2030)
        7.3.3 United States Market Size and Forecast (2019-2030)
        7.3.4 Canada Market Size and Forecast (2019-2030)
        7.3.5 Mexico Market Size and Forecast (2019-2030)

8 Europe
    8.1 Europe Age Related Macular Degeneration Drugs Sales Quantity by Type (2019-2030)
    8.2 Europe Age Related Macular Degeneration Drugs Sales Quantity by Application (2019-2030)
    8.3 Europe Age Related Macular Degeneration Drugs Market Size by Country
        8.3.1 Europe Age Related Macular Degeneration Drugs Sales Quantity by Country (2019-2030)
        8.3.2 Europe Age Related Macular Degeneration Drugs Consumption Value by Country (2019-2030)
        8.3.3 Germany Market Size and Forecast (2019-2030)
        8.3.4 France Market Size and Forecast (2019-2030)
        8.3.5 United Kingdom Market Size and Forecast (2019-2030)
        8.3.6 Russia Market Size and Forecast (2019-2030)
        8.3.7 Italy Market Size and Forecast (2019-2030)

9 Asia-Pacific
    9.1 Asia-Pacific Age Related Macular Degeneration Drugs Sales Quantity by Type (2019-2030)
    9.2 Asia-Pacific Age Related Macular Degeneration Drugs Sales Quantity by Application (2019-2030)
    9.3 Asia-Pacific Age Related Macular Degeneration Drugs Market Size by Region
        9.3.1 Asia-Pacific Age Related Macular Degeneration Drugs Sales Quantity by Region (2019-2030)
        9.3.2 Asia-Pacific Age Related Macular Degeneration Drugs Consumption Value by Region (2019-2030)
        9.3.3 China Market Size and Forecast (2019-2030)
        9.3.4 Japan Market Size and Forecast (2019-2030)
        9.3.5 Korea Market Size and Forecast (2019-2030)
        9.3.6 India Market Size and Forecast (2019-2030)
        9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
        9.3.8 Australia Market Size and Forecast (2019-2030)

10 South America
    10.1 South America Age Related Macular Degeneration Drugs Sales Quantity by Type (2019-2030)
    10.2 South America Age Related Macular Degeneration Drugs Sales Quantity by Application (2019-2030)
    10.3 South America Age Related Macular Degeneration Drugs Market Size by Country
        10.3.1 South America Age Related Macular Degeneration Drugs Sales Quantity by Country (2019-2030)
        10.3.2 South America Age Related Macular Degeneration Drugs Consumption Value by Country (2019-2030)
        10.3.3 Brazil Market Size and Forecast (2019-2030)
        10.3.4 Argentina Market Size and Forecast (2019-2030)

11 Middle East & Africa
    11.1 Middle East & Africa Age Related Macular Degeneration Drugs Sales Quantity by Type (2019-2030)
    11.2 Middle East & Africa Age Related Macular Degeneration Drugs Sales Quantity by Application (2019-2030)
    11.3 Middle East & Africa Age Related Macular Degeneration Drugs Market Size by Country
        11.3.1 Middle East & Africa Age Related Macular Degeneration Drugs Sales Quantity by Country (2019-2030)
        11.3.2 Middle East & Africa Age Related Macular Degeneration Drugs Consumption Value by Country (2019-2030)
        11.3.3 Turkey Market Size and Forecast (2019-2030)
        11.3.4 Egypt Market Size and Forecast (2019-2030)
        11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
        11.3.6 South Africa Market Size and Forecast (2019-2030)

12 Market Dynamics
    12.1 Age Related Macular Degeneration Drugs Market Drivers
    12.2 Age Related Macular Degeneration Drugs Market Restraints
    12.3 Age Related Macular Degeneration Drugs Trends Analysis
    12.4 Porters Five Forces Analysis
        12.4.1 Threat of New Entrants
        12.4.2 Bargaining Power of Suppliers
        12.4.3 Bargaining Power of Buyers
        12.4.4 Threat of Substitutes
        12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain
    13.1 Raw Material of Age Related Macular Degeneration Drugs and Key Manufacturers
    13.2 Manufacturing Costs Percentage of Age Related Macular Degeneration Drugs
    13.3 Age Related Macular Degeneration Drugs Production Process
    13.4 Age Related Macular Degeneration Drugs Industrial Chain

14 Shipments by Distribution Channel
    14.1 Sales Channel
        14.1.1 Direct to End-User
        14.1.2 Distributors
    14.2 Age Related Macular Degeneration Drugs Typical Distributors
    14.3 Age Related Macular Degeneration Drugs Typical Customers

15 Research Findings and Conclusion

16 Appendix
    16.1 Methodology
    16.2 Research Process and Data Source
    16.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Age Related Macular Degeneration Drugs Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Table 2. Global Age Related Macular Degeneration Drugs Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
    Table 3. Novartis Basic Information, Manufacturing Base and Competitors
    Table 4. Novartis Major Business
    Table 5. Novartis Age Related Macular Degeneration Drugs Product and Services
    Table 6. Novartis Age Related Macular Degeneration Drugs Sales Quantity (K MT), Average Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 7. Novartis Recent Developments/Updates
    Table 8. Bayer Healthcare Basic Information, Manufacturing Base and Competitors
    Table 9. Bayer Healthcare Major Business
    Table 10. Bayer Healthcare Age Related Macular Degeneration Drugs Product and Services
    Table 11. Bayer Healthcare Age Related Macular Degeneration Drugs Sales Quantity (K MT), Average Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 12. Bayer Healthcare Recent Developments/Updates
    Table 13. Roche Basic Information, Manufacturing Base and Competitors
    Table 14. Roche Major Business
    Table 15. Roche Age Related Macular Degeneration Drugs Product and Services
    Table 16. Roche Age Related Macular Degeneration Drugs Sales Quantity (K MT), Average Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 17. Roche Recent Developments/Updates
    Table 18. Neurotech Pharmaceuticals Basic Information, Manufacturing Base and Competitors
    Table 19. Neurotech Pharmaceuticals Major Business
    Table 20. Neurotech Pharmaceuticals Age Related Macular Degeneration Drugs Product and Services
    Table 21. Neurotech Pharmaceuticals Age Related Macular Degeneration Drugs Sales Quantity (K MT), Average Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 22. Neurotech Pharmaceuticals Recent Developments/Updates
    Table 23. Regeneron Pharmaceuticals Basic Information, Manufacturing Base and Competitors
    Table 24. Regeneron Pharmaceuticals Major Business
    Table 25. Regeneron Pharmaceuticals Age Related Macular Degeneration Drugs Product and Services
    Table 26. Regeneron Pharmaceuticals Age Related Macular Degeneration Drugs Sales Quantity (K MT), Average Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 27. Regeneron Pharmaceuticals Recent Developments/Updates
    Table 28. Allergan Basic Information, Manufacturing Base and Competitors
    Table 29. Allergan Major Business
    Table 30. Allergan Age Related Macular Degeneration Drugs Product and Services
    Table 31. Allergan Age Related Macular Degeneration Drugs Sales Quantity (K MT), Average Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 32. Allergan Recent Developments/Updates
    Table 33. Global Age Related Macular Degeneration Drugs Sales Quantity by Manufacturer (2019-2024) & (K MT)
    Table 34. Global Age Related Macular Degeneration Drugs Revenue by Manufacturer (2019-2024) & (USD Million)
    Table 35. Global Age Related Macular Degeneration Drugs Average Price by Manufacturer (2019-2024) & (USD/MT)
    Table 36. Market Position of Manufacturers in Age Related Macular Degeneration Drugs, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2023
    Table 37. Head Office and Age Related Macular Degeneration Drugs Production Site of Key Manufacturer
    Table 38. Age Related Macular Degeneration Drugs Market: Company Product Type Footprint
    Table 39. Age Related Macular Degeneration Drugs Market: Company Product Application Footprint
    Table 40. Age Related Macular Degeneration Drugs New Market Entrants and Barriers to Market Entry
    Table 41. Age Related Macular Degeneration Drugs Mergers, Acquisition, Agreements, and Collaborations
    Table 42. Global Age Related Macular Degeneration Drugs Sales Quantity by Region (2019-2024) & (K MT)
    Table 43. Global Age Related Macular Degeneration Drugs Sales Quantity by Region (2025-2030) & (K MT)
    Table 44. Global Age Related Macular Degeneration Drugs Consumption Value by Region (2019-2024) & (USD Million)
    Table 45. Global Age Related Macular Degeneration Drugs Consumption Value by Region (2025-2030) & (USD Million)
    Table 46. Global Age Related Macular Degeneration Drugs Average Price by Region (2019-2024) & (USD/MT)
    Table 47. Global Age Related Macular Degeneration Drugs Average Price by Region (2025-2030) & (USD/MT)
    Table 48. Global Age Related Macular Degeneration Drugs Sales Quantity by Type (2019-2024) & (K MT)
    Table 49. Global Age Related Macular Degeneration Drugs Sales Quantity by Type (2025-2030) & (K MT)
    Table 50. Global Age Related Macular Degeneration Drugs Consumption Value by Type (2019-2024) & (USD Million)
    Table 51. Global Age Related Macular Degeneration Drugs Consumption Value by Type (2025-2030) & (USD Million)
    Table 52. Global Age Related Macular Degeneration Drugs Average Price by Type (2019-2024) & (USD/MT)
    Table 53. Global Age Related Macular Degeneration Drugs Average Price by Type (2025-2030) & (USD/MT)
    Table 54. Global Age Related Macular Degeneration Drugs Sales Quantity by Application (2019-2024) & (K MT)
    Table 55. Global Age Related Macular Degeneration Drugs Sales Quantity by Application (2025-2030) & (K MT)
    Table 56. Global Age Related Macular Degeneration Drugs Consumption Value by Application (2019-2024) & (USD Million)
    Table 57. Global Age Related Macular Degeneration Drugs Consumption Value by Application (2025-2030) & (USD Million)
    Table 58. Global Age Related Macular Degeneration Drugs Average Price by Application (2019-2024) & (USD/MT)
    Table 59. Global Age Related Macular Degeneration Drugs Average Price by Application (2025-2030) & (USD/MT)
    Table 60. North America Age Related Macular Degeneration Drugs Sales Quantity by Type (2019-2024) & (K MT)
    Table 61. North America Age Related Macular Degeneration Drugs Sales Quantity by Type (2025-2030) & (K MT)
    Table 62. North America Age Related Macular Degeneration Drugs Sales Quantity by Application (2019-2024) & (K MT)
    Table 63. North America Age Related Macular Degeneration Drugs Sales Quantity by Application (2025-2030) & (K MT)
    Table 64. North America Age Related Macular Degeneration Drugs Sales Quantity by Country (2019-2024) & (K MT)
    Table 65. North America Age Related Macular Degeneration Drugs Sales Quantity by Country (2025-2030) & (K MT)
    Table 66. North America Age Related Macular Degeneration Drugs Consumption Value by Country (2019-2024) & (USD Million)
    Table 67. North America Age Related Macular Degeneration Drugs Consumption Value by Country (2025-2030) & (USD Million)
    Table 68. Europe Age Related Macular Degeneration Drugs Sales Quantity by Type (2019-2024) & (K MT)
    Table 69. Europe Age Related Macular Degeneration Drugs Sales Quantity by Type (2025-2030) & (K MT)
    Table 70. Europe Age Related Macular Degeneration Drugs Sales Quantity by Application (2019-2024) & (K MT)
    Table 71. Europe Age Related Macular Degeneration Drugs Sales Quantity by Application (2025-2030) & (K MT)
    Table 72. Europe Age Related Macular Degeneration Drugs Sales Quantity by Country (2019-2024) & (K MT)
    Table 73. Europe Age Related Macular Degeneration Drugs Sales Quantity by Country (2025-2030) & (K MT)
    Table 74. Europe Age Related Macular Degeneration Drugs Consumption Value by Country (2019-2024) & (USD Million)
    Table 75. Europe Age Related Macular Degeneration Drugs Consumption Value by Country (2025-2030) & (USD Million)
    Table 76. Asia-Pacific Age Related Macular Degeneration Drugs Sales Quantity by Type (2019-2024) & (K MT)
    Table 77. Asia-Pacific Age Related Macular Degeneration Drugs Sales Quantity by Type (2025-2030) & (K MT)
    Table 78. Asia-Pacific Age Related Macular Degeneration Drugs Sales Quantity by Application (2019-2024) & (K MT)
    Table 79. Asia-Pacific Age Related Macular Degeneration Drugs Sales Quantity by Application (2025-2030) & (K MT)
    Table 80. Asia-Pacific Age Related Macular Degeneration Drugs Sales Quantity by Region (2019-2024) & (K MT)
    Table 81. Asia-Pacific Age Related Macular Degeneration Drugs Sales Quantity by Region (2025-2030) & (K MT)
    Table 82. Asia-Pacific Age Related Macular Degeneration Drugs Consumption Value by Region (2019-2024) & (USD Million)
    Table 83. Asia-Pacific Age Related Macular Degeneration Drugs Consumption Value by Region (2025-2030) & (USD Million)
    Table 84. South America Age Related Macular Degeneration Drugs Sales Quantity by Type (2019-2024) & (K MT)
    Table 85. South America Age Related Macular Degeneration Drugs Sales Quantity by Type (2025-2030) & (K MT)
    Table 86. South America Age Related Macular Degeneration Drugs Sales Quantity by Application (2019-2024) & (K MT)
    Table 87. South America Age Related Macular Degeneration Drugs Sales Quantity by Application (2025-2030) & (K MT)
    Table 88. South America Age Related Macular Degeneration Drugs Sales Quantity by Country (2019-2024) & (K MT)
    Table 89. South America Age Related Macular Degeneration Drugs Sales Quantity by Country (2025-2030) & (K MT)
    Table 90. South America Age Related Macular Degeneration Drugs Consumption Value by Country (2019-2024) & (USD Million)
    Table 91. South America Age Related Macular Degeneration Drugs Consumption Value by Country (2025-2030) & (USD Million)
    Table 92. Middle East & Africa Age Related Macular Degeneration Drugs Sales Quantity by Type (2019-2024) & (K MT)
    Table 93. Middle East & Africa Age Related Macular Degeneration Drugs Sales Quantity by Type (2025-2030) & (K MT)
    Table 94. Middle East & Africa Age Related Macular Degeneration Drugs Sales Quantity by Application (2019-2024) & (K MT)
    Table 95. Middle East & Africa Age Related Macular Degeneration Drugs Sales Quantity by Application (2025-2030) & (K MT)
    Table 96. Middle East & Africa Age Related Macular Degeneration Drugs Sales Quantity by Region (2019-2024) & (K MT)
    Table 97. Middle East & Africa Age Related Macular Degeneration Drugs Sales Quantity by Region (2025-2030) & (K MT)
    Table 98. Middle East & Africa Age Related Macular Degeneration Drugs Consumption Value by Region (2019-2024) & (USD Million)
    Table 99. Middle East & Africa Age Related Macular Degeneration Drugs Consumption Value by Region (2025-2030) & (USD Million)
    Table 100. Age Related Macular Degeneration Drugs Raw Material
    Table 101. Key Manufacturers of Age Related Macular Degeneration Drugs Raw Materials
    Table 102. Age Related Macular Degeneration Drugs Typical Distributors
    Table 103. Age Related Macular Degeneration Drugs Typical Customers
List of Figures
    Figure 1. Age Related Macular Degeneration Drugs Picture
    Figure 2. Global Age Related Macular Degeneration Drugs Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Figure 3. Global Age Related Macular Degeneration Drugs Consumption Value Market Share by Type in 2023
    Figure 4. Lucentis Examples
    Figure 5. Eylea Examples
    Figure 6. Avastin Examples
    Figure 7. Squalamine Examples
    Figure 8. Conercept Examples
    Figure 9. Lampalizamab Examples
    Figure 10. Others Examples
    Figure 11. Global Age Related Macular Degeneration Drugs Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
    Figure 12. Global Age Related Macular Degeneration Drugs Consumption Value Market Share by Application in 2023
    Figure 13. 50-60 Years Old Examples
    Figure 14. 60-70 Years Old Examples
    Figure 15. Others Examples
    Figure 16. Global Age Related Macular Degeneration Drugs Consumption Value, (USD Million): 2019 & 2023 & 2030
    Figure 17. Global Age Related Macular Degeneration Drugs Consumption Value and Forecast (2019-2030) & (USD Million)
    Figure 18. Global Age Related Macular Degeneration Drugs Sales Quantity (2019-2030) & (K MT)
    Figure 19. Global Age Related Macular Degeneration Drugs Average Price (2019-2030) & (USD/MT)
    Figure 20. Global Age Related Macular Degeneration Drugs Sales Quantity Market Share by Manufacturer in 2023
    Figure 21. Global Age Related Macular Degeneration Drugs Consumption Value Market Share by Manufacturer in 2023
    Figure 22. Producer Shipments of Age Related Macular Degeneration Drugs by Manufacturer Sales Quantity ($MM) and Market Share (%): 2023
    Figure 23. Top 3 Age Related Macular Degeneration Drugs Manufacturer (Consumption Value) Market Share in 2023
    Figure 24. Top 6 Age Related Macular Degeneration Drugs Manufacturer (Consumption Value) Market Share in 2023
    Figure 25. Global Age Related Macular Degeneration Drugs Sales Quantity Market Share by Region (2019-2030)
    Figure 26. Global Age Related Macular Degeneration Drugs Consumption Value Market Share by Region (2019-2030)
    Figure 27. North America Age Related Macular Degeneration Drugs Consumption Value (2019-2030) & (USD Million)
    Figure 28. Europe Age Related Macular Degeneration Drugs Consumption Value (2019-2030) & (USD Million)
    Figure 29. Asia-Pacific Age Related Macular Degeneration Drugs Consumption Value (2019-2030) & (USD Million)
    Figure 30. South America Age Related Macular Degeneration Drugs Consumption Value (2019-2030) & (USD Million)
    Figure 31. Middle East & Africa Age Related Macular Degeneration Drugs Consumption Value (2019-2030) & (USD Million)
    Figure 32. Global Age Related Macular Degeneration Drugs Sales Quantity Market Share by Type (2019-2030)
    Figure 33. Global Age Related Macular Degeneration Drugs Consumption Value Market Share by Type (2019-2030)
    Figure 34. Global Age Related Macular Degeneration Drugs Average Price by Type (2019-2030) & (USD/MT)
    Figure 35. Global Age Related Macular Degeneration Drugs Sales Quantity Market Share by Application (2019-2030)
    Figure 36. Global Age Related Macular Degeneration Drugs Consumption Value Market Share by Application (2019-2030)
    Figure 37. Global Age Related Macular Degeneration Drugs Average Price by Application (2019-2030) & (USD/MT)
    Figure 38. North America Age Related Macular Degeneration Drugs Sales Quantity Market Share by Type (2019-2030)
    Figure 39. North America Age Related Macular Degeneration Drugs Sales Quantity Market Share by Application (2019-2030)
    Figure 40. North America Age Related Macular Degeneration Drugs Sales Quantity Market Share by Country (2019-2030)
    Figure 41. North America Age Related Macular Degeneration Drugs Consumption Value Market Share by Country (2019-2030)
    Figure 42. United States Age Related Macular Degeneration Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 43. Canada Age Related Macular Degeneration Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 44. Mexico Age Related Macular Degeneration Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 45. Europe Age Related Macular Degeneration Drugs Sales Quantity Market Share by Type (2019-2030)
    Figure 46. Europe Age Related Macular Degeneration Drugs Sales Quantity Market Share by Application (2019-2030)
    Figure 47. Europe Age Related Macular Degeneration Drugs Sales Quantity Market Share by Country (2019-2030)
    Figure 48. Europe Age Related Macular Degeneration Drugs Consumption Value Market Share by Country (2019-2030)
    Figure 49. Germany Age Related Macular Degeneration Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 50. France Age Related Macular Degeneration Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 51. United Kingdom Age Related Macular Degeneration Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 52. Russia Age Related Macular Degeneration Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 53. Italy Age Related Macular Degeneration Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 54. Asia-Pacific Age Related Macular Degeneration Drugs Sales Quantity Market Share by Type (2019-2030)
    Figure 55. Asia-Pacific Age Related Macular Degeneration Drugs Sales Quantity Market Share by Application (2019-2030)
    Figure 56. Asia-Pacific Age Related Macular Degeneration Drugs Sales Quantity Market Share by Region (2019-2030)
    Figure 57. Asia-Pacific Age Related Macular Degeneration Drugs Consumption Value Market Share by Region (2019-2030)
    Figure 58. China Age Related Macular Degeneration Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 59. Japan Age Related Macular Degeneration Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 60. Korea Age Related Macular Degeneration Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 61. India Age Related Macular Degeneration Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 62. Southeast Asia Age Related Macular Degeneration Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 63. Australia Age Related Macular Degeneration Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 64. South America Age Related Macular Degeneration Drugs Sales Quantity Market Share by Type (2019-2030)
    Figure 65. South America Age Related Macular Degeneration Drugs Sales Quantity Market Share by Application (2019-2030)
    Figure 66. South America Age Related Macular Degeneration Drugs Sales Quantity Market Share by Country (2019-2030)
    Figure 67. South America Age Related Macular Degeneration Drugs Consumption Value Market Share by Country (2019-2030)
    Figure 68. Brazil Age Related Macular Degeneration Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 69. Argentina Age Related Macular Degeneration Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 70. Middle East & Africa Age Related Macular Degeneration Drugs Sales Quantity Market Share by Type (2019-2030)
    Figure 71. Middle East & Africa Age Related Macular Degeneration Drugs Sales Quantity Market Share by Application (2019-2030)
    Figure 72. Middle East & Africa Age Related Macular Degeneration Drugs Sales Quantity Market Share by Region (2019-2030)
    Figure 73. Middle East & Africa Age Related Macular Degeneration Drugs Consumption Value Market Share by Region (2019-2030)
    Figure 74. Turkey Age Related Macular Degeneration Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 75. Egypt Age Related Macular Degeneration Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 76. Saudi Arabia Age Related Macular Degeneration Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 77. South Africa Age Related Macular Degeneration Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 78. Age Related Macular Degeneration Drugs Market Drivers
    Figure 79. Age Related Macular Degeneration Drugs Market Restraints
    Figure 80. Age Related Macular Degeneration Drugs Market Trends
    Figure 81. Porters Five Forces Analysis
    Figure 82. Manufacturing Cost Structure Analysis of Age Related Macular Degeneration Drugs in 2023
    Figure 83. Manufacturing Process Analysis of Age Related Macular Degeneration Drugs
    Figure 84. Age Related Macular Degeneration Drugs Industrial Chain
    Figure 85. Sales Quantity Channel: Direct to End-User vs Distributors
    Figure 86. Direct Channel Pros & Cons
    Figure 87. Indirect Channel Pros & Cons
    Figure 88. Methodology
    Figure 89. Research Process and Data Source

Companies Mentioned

Novartis
Bayer Healthcare
Roche
Neurotech Pharmaceuticals
Regeneron Pharmaceuticals
Allergan